Halozyme to report Q3 2026 results on Nov 5 with a conference call for investors.

Halozyme Therapeutics announced it will release its financial and operating results for the third quarter of 2026 on November 5, 2026, after market close. The company will hold a conference call at 1:30 pm PT/4:30 pm ET the same day to discuss the results, accessible via pre-registration online and replayable on its website. Halozyme is known for its ENHANZE drug delivery technology and is expanding its portfolio with Hypercon™ and Aerocon™ technologies to improve subcutaneous drug delivery. Investors and interested parties can follow the call to get insights into the company’s latest performance and developments.

As of Oct 22, 2026 19:13 WIB, Halozyme Therapeutics shares trade at USD 125.23 on Pluang, showing a modest 0.32% gain for the day. Despite the positive price movement, the platform records a strong sell sentiment with 99% of orders to sell. The company’s market capitalization stands at $14.17 billion, highlighting its significant presence in the health sector.